Wnt inhibitory factor (WIF)-1 inhibits osteoblastic differentiation in mouse embryonic mesenchymal cells

Bone

Volumn 44, Issue 6, 2009, Pages 1069-1077

  Cho, Sun Wook ^a,b   Yang, Jae Yeon ^b   Sun, Hyun Jin ^b   Jung, Ju Yeon ^b   Her, Sun Ju ^b   Cho, Hwa Young ^a,b   Choi, Hyung Jin ^a,b   Kim, Sang Wan ^a,c   Kim, Seong Yeon ^a,b   Shin, Chan Soo ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

Author keywords

Adipogenesis; Mesenchymal cell; Osteoblastic differentiation; Wnt; Wnt inhibitory factor 1

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; MESSENGER RNA; OSTEOCALCIN; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; WNT INHIBITORY FACTOR 1; WNT1 PROTEIN;

ADIPOGENESIS; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; MESENCHYME CELL; MOUSE; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

3T3-L1 CELLS; ADIPOGENESIS; ALKALINE PHOSPHATASE; ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE; COLLAGEN TYPE I; CORE BINDING FACTOR ALPHA 1 SUBUNIT; ENZYME ACTIVATION; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESENCHYMAL STEM CELLS; MICE; OSTEOBLASTS; OSTEOCALCIN; OSTEOGENESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TCF TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 67349101267     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.02.012     Document Type: Article

References (30)

1. Cadigan K.M., and Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 11 (1997) 3286-3305
2. He X., Semenov M., Tamai K., and Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 131 (2004) 1663-1677
3. Bodine P.V., and Komm B.S. Wnt signaling and osteoblastogenesis. Rev. Endocr. Metab. Disord. 7 (2006) 33-39
4. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70 (2002) 11-19
5. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 (2001) 513-523
6. Babij P., Zhao W., Small C., Kharode Y., Yaworsky P.J., Bouxsein M.L., et al. High bone mass in mice expressing a mutant LRP5 gene. J. Bone Miner. Res. 18 (2003) 960-974
7. Holmen S.L., Giambernardi T.A., Zylstra C.R., Buckner-Berghuis B.D., Resau J.H., Hess J.F., et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J. Bone Miner. Res. 19 (2004) 2033-2040
8. Nusse R., and Varmus H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31 (1982) 99-109
9. Polakis P. The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev. 9 (1999) 15-21
10. Shimizu H., Julius M.A., Giarre M., Zheng Z., Brown A.M., and Kitajewski J. Transformation by Wnt family proteins correlates with regulation of beta-catenin. Cell. Growth Differ. 8 (1997) 1349-1358
11. Mao B., Wu W., Davidson G., Marhold J., Li M., Mechler B.M., et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417 (2002) 664-667
12. Hsieh J.C., Kodjabachian L., Rebbert M.L., Rattner A., Smallwood P.M., Samos C.H., et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398 (1999) 431-436
13. Wang S., Krinks M., Lin K., Luyten F.P., and Moos Jr. M. Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell 88 (1997) 757-766
14. Vaes B.L., Dechering K.J., Feijen A., Hendriks J.M., Lefevre C., Mummery C.L., et al. Comprehensive microarray analysis of bone morphogenetic protein 2-induced osteoblast differentiation resulting in the identification of novel markers for bone development. J. Bone Miner. Res. 17 (2002) 2106-2118
15. van der Horst G., van der Werf S.M., Farih-Sips H., van Bezooijen R.L., Lowik C.W., and Karperien M. Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. J. Bone Miner. Res. 20 (2005) 1867-1877
16. Furlan F., Lecanda F., Screen J., and Civitelli R. Proliferation, differentiation and apoptosis in connexin43-null osteoblasts. Cell. Commun. Adhes. 8 (2001) 367-371
17. Shibamoto S., Higano K., Takada R., Ito F., Takeichi M., and Takada S. Cytoskeletal reorganization by soluble Wnt-3a protein signalling. Genes Cells. 3 (1998) 659-670
18. Galli L.M., Barnes T., Cheng T., Acosta L., Anglade A., Willert K., et al. Differential inhibition of Wnt-3a by Sfrp-1, Sfrp-2, and Sfrp-3. Dev. Dyn. 235 (2006) 681-690
19. Cho S.W., Her S.J., Sun H.J., Choi O.K., Yang J.Y., Kim S.W., et al. Differential effects of secreted frizzled-related proteins (sFRPs) on osteoblastic differentiation of mouse mesenchymal cells and apoptosis of osteoblasts. Biochem. Biophys. Res. Commun. 367 (2008) 399-405
20. Reguart N., He B., Xu Z., You L., Lee A.Y., Mazieres J., et al. Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem. Biophys. Res. Commun. 323 (2004) 229-234
21. Nuttall M.E., and Gimble J.M. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr. Opin. Pharmacol. 4 (2004) 290-294
22. Bennett C.N., Ross S.E., Longo K.A., Bajnok L., Hemati N., Johnson K.W., et al. Regulation of Wnt signaling during adipogenesis. J. Biol. Chem. 277 (2002) 30998-31004
23. Chung Y.S., Baylink D.J., Srivastava A.K., Amaar Y., Tapia B., Kasukawa Y., et al. Effects of secreted frizzled-related protein 3 on osteoblasts in vitro. J. Bone Miner. Res. 19 (2004) 1395-1402
24. Melkonyan H.S., Chang W.C., Shapiro J.P., Mahadevappa M., Fitzpatrick P.A., Kiefer M.C., et al. SARPs: a family of secreted apoptosis-related proteins. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13636-13641
25. Ellies D.L., Church V., Francis-West P., and Lumsden A. The WNT antagonist cSFRP2 modulates programmed cell death in the developing hindbrain. Development 127 (2000) 5285-5295
26. Rawadi G., Vayssiere B., Dunn F., Baron R., and Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J. Bone Miner. Res. 18 (2003) 1842-1853
27. Nakashima A., Katagiri T., and Tamura M. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J. Biol. Chem. 280 (2005) 37660-37668
28. Yang L., Yamasaki K., Shirakata Y., Dai X., Tokumaru S., Yahata Y., et al. Bone morphogenetic protein-2 modulates Wnt and frizzled expression and enhances the canonical pathway of Wnt signaling in normal keratinocytes. J. Dermatol. Sci. 42 (2006) 111-119
29. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., and Shaughnessy Jr. J.D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109 (2007) 2106-2111
30. Li X., K.S.W., Niu Q., Grisanti M., Tan H., Simonet W.S., et al. Treatment with an anti-sclerostin antibody directly stimulates bone formation in a dose-dependent manner in ovariectomized rats with established osteopenia. J. Bone Miner. Res. 22 (2007) S65